Creo Medical Group PLC US Clinical Education Programme enters Phase II (7366L)

TIDMCREO

RNS Number : 7366L

Creo Medical Group PLC

10 September 2019

Creo Medical Group plc

("Creo" or the "Company")

US Clinical Education Programme enters Phase II

First training course delivered by key US adopter trained by Creo

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has entered phase two of its Clinical Education Programme in the US, with the successful completion of the first Speedboat training course delivered by a US clinician trained as part of Creo's programme. As part of this new phase, three additional US clinicians have been trained by a US GI Endoscopists who performed his first clinical case earlier this year (RNS 1927N, 16 January 2019) and practices at a major US hospital, which was one of the first to place commercial orders for the Company's Speedboat device.

Creo's Clinical Education Programme ensures that first adopters of Speedboat, having been carefully mentored, can deliver training in this emerging field of surgical endoscopy to their fellow clinicians at a consistently high standard, safeguarding quality control and ensuring best patient outcomes. This new phase of the programme will see Creo establish the first in a series of US training centres run by US key opinion leaders who have already adopted Speedboat.

About Speedboat and CROMA

Speedboat is the first in a range of endoscopic minimally invasive surgical devices to be cleared for use with the Company's CROMA Advanced Energy platform, which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation. A growing number of GI Endoscopists in the UK, South Africa, Mainland Europe and the US have now performed multiple successful treatments using Speedboat, removing lesions in both upper and lower GI cases.

Typically, instead of having to undergo surgery under general anaesthetic, these patients only needed sedation and were treated as day patients. As a result, Speedboat helps to reduce the risks associated with alternative open, laparoscopic and existing endoscopic procedures, reducing the length of stay in hospital for the patient and the cost of treatment by transferring therapy from the operating theatre to the endoscopy room.

Craig Gulliford, Creo's Chief Executive Officer, commented:

"To have one of our first key adopters in Phoenix, Arizona, who was trained as part of the first wave of our US Clinical Education Programme, now training fellow clinicians in the use of Speedboat is a major milestone for the successful commercial roll-out of our first product. It also marks the first in a series of training centres to deliver these courses in sites across the US, and similarly across other distributor markets for Creo.

"Whilst we remain in the early stages of roll-out, we expect to see a cascade effect and an increasing number of endoscopists trained consistently to the highest standards through our Clinical Education Programme, resulting in the wider adoption of our technology in the US."

 
 Creo Medical Group plc 
 Richard Rees (CFO)                                                    [phone] 
 
 Cenkos Securities                                                     [phone] 
 Stephen Keys / Cameron MacRitchie 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Paul McManus                                                     Mob: [phone] 
 Lianne Cawthorne                                                 Mob: [phone] 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiofrequency energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar RF for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes that its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RESDBGDCCBGBGCC

(END) Dow Jones Newswires

September 10, 2019 02:01 ET (06:01 GMT)